{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:19Z","timestamp":1790352559115,"version":"4.1.0"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00281-018-0700-2","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T12:18:11Z","timestamp":1536581891000},"page":"5-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenmann J, Virus interference I (1957) The interferon. Proc R Soc Lond B Biol Sci 147:258\u2013267","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8\u201332","journal-title":"Immunol Rev"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.pharmthera.2004.12.002","volume":"106","author":"CD Krause","year":"2005","unstructured":"Krause CD, Pestka S (2005) Evolution of the class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 106:299\u2013346","journal-title":"Pharmacol Ther"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC (2005) Mechanisms of type-I- and type-II-interferon mediated signalling. Nat Rev Immunol 5:375\u2013386","journal-title":"Nat Rev Immunol"},{"key":"700_CR5","doi-asserted-by":"crossref","unstructured":"de Weerd NA, Samarajiwa SA, Hertzog PJ (2007) Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053\u201320057","DOI":"10.1074\/jbc.R700006200"},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"20047","DOI":"10.1074\/jbc.R700004200","volume":"282","author":"S Pestka","year":"2007","unstructured":"Pestka S (2007) The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282:20047\u201320051","journal-title":"J Biol Chem"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-065X.1999.tb01327.x","volume":"170","author":"DF Tough","year":"1999","unstructured":"Tough DF, Sun S, Zhang X, Sprent J (1999) Stimulation of naive and memory T cells by cytokines. Immunol Rev 170:39\u201347","journal-title":"Immunol Rev"},{"key":"700_CR8","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1016\/S0021-9258(17)43764-1","volume":"258","author":"JR Ortaldo","year":"1983","unstructured":"Ortaldo JR, Mason A, Rehberg E et al (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 258:15011\u201315015","journal-title":"J Biol Chem"},{"issue":"Part A","key":"700_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0076-6879(81)78094-7","volume":"78","author":"K Cantell","year":"1981","unstructured":"Cantell K, Hirvonen S, Kauppinen HL, Myllyla G (1981) Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 78(Part A):29\u201338","journal-title":"Methods Enzymol"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(79)90770-0","volume":"313","author":"H Mellstedt","year":"1979","unstructured":"Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H (1979) Interferon therapy in myelomatosis. Lancet 313:245\u2013247","journal-title":"Lancet"},{"issue":"5\u20136","key":"700_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","volume":"18","author":"LA Kujawski","year":"2007","unstructured":"Kujawski LA, Talpaz M (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 18(5\u20136):459\u2013471","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"700_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428190801927510","volume":"49","author":"F Guilhot","year":"2008","unstructured":"Guilhot F, Roy L, Saulnier PJ et al (2008) Immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma 49(4):629\u2013634","journal-title":"Leuk Lymphoma"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MAG Essers","year":"2009","unstructured":"Essers MAG, Offner S, Blanco-Bose WE et al (2009) IFNa activates dormant haematopoietic stem cells in vivo. Nature 458:904\u2013908","journal-title":"Nature"},{"issue":"3","key":"700_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri2726","volume":"10","author":"A Trumpp","year":"2010","unstructured":"Trumpp A, Essers M, Wilson A (2010) Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10(3):201\u2013209","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"700_CR15","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markev\u00e4rn B, Remes K, Stentoft J, Nordic CML Study Group et al (2011) Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118(12):3228\u20133235","journal-title":"Blood"},{"issue":"3","key":"700_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2174\/138945011794815301","volume":"12","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K (2011) Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets 12(3):420\u2013428","journal-title":"Curr Drug Targets"},{"issue":"Suppl 2","key":"700_CR17","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","volume":"94","author":"M Talpaz","year":"2015","unstructured":"Talpaz M, Mercer J, Hehlmann R (2015) The interferon-alpha revival in CML. Ann Hematol 94(Suppl 2):S195\u2013S207","journal-title":"Ann Hematol"},{"issue":"3","key":"700_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.beha.2016.10.017","volume":"29","author":"E Cayssials","year":"2016","unstructured":"Cayssials E, Guilhot F (2016) Beyond tyrosine kinase inhibitors: combinations and other agents. Best Pract Res Clin Haematol 29(3):271\u2013283","journal-title":"Best Pract Res Clin Haematol"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037\u20132040","journal-title":"Blood"},{"issue":"11","key":"700_CR20","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22(11):1990\u20131998","journal-title":"Leukemia"},{"issue":"18","key":"700_CR21","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Mesa RA, Hoffman R (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706\u20134715","journal-title":"Blood"},{"issue":"3","key":"700_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/138945011794815275","volume":"12","author":"HC Hasselbalch","year":"2011","unstructured":"Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ (2011) Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 12(3):392\u2013419","journal-title":"Curr Drug Targets"},{"issue":"6","key":"700_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1586\/ehm.11.63","volume":"4","author":"HC Hasselbalch","year":"2011","unstructured":"Hasselbalch HC (2011) A new era of interferon-alpha2 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 4(6):637\u2013655","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"700_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ehm.12.69","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver RT, Kiladjian JJ, Hasselbalch HC (2013) Interferon in the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Rev. Hematology 6(1):49\u201358","journal-title":"Expert Rev. Hematology"},{"issue":"4","key":"700_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1586\/17474086.2015.1045409","volume":"8","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Silver RT (2015) Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? Expert Rev Hematol 8(4):439\u2013445","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"700_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30(4):776\u2013781","journal-title":"Leukemia"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/cncr.21900","volume":"106","author":"J Samuelsson","year":"2006","unstructured":"Samuelsson J, Hasselbalch H, Bruserud O et al (2006) A phase II trial of pegylated interferon alpha- 2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106:2397\u20132405","journal-title":"Cancer"},{"issue":"4","key":"700_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00277-006-0214-1","volume":"86","author":"C Steimle","year":"2007","unstructured":"Steimle C, Lehmann U, Temerinac S et al (2007) Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 86(4):239\u2013244","journal-title":"Ann Hematol"},{"issue":"8","key":"700_CR29","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S et al (2008) Pegylated interferon-alfa-2a induces complete haematological and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072","journal-title":"Blood"},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00277-008-0498-4","volume":"87","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2008) Complete molecular remission of polycythemia vera during long-term treatment with pegylated interferon alpha-2b. Ann Hematol 87:847\u2013850","journal-title":"Ann Hematol"},{"issue":"6","key":"700_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1179\/102453309X12473408860587","volume":"14","author":"TS Larsen","year":"2009","unstructured":"Larsen TS, M\u00f8ller MB, de Stricker K et al (2009) Minimal residual disease and normalization of the bone marrow after long-term treatment with alphainterferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology 14(6):331\u2013334","journal-title":"Hematology"},{"issue":"32","key":"700_CR32","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418\u20135424","journal-title":"J Clin Oncol"},{"key":"700_CR33","doi-asserted-by":"crossref","unstructured":"Larsen TS, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, R\u00f8nnov-Jessen D, M\u00f8ller MB, de Stricker K, Vestergaard H, Hasselbalch HC (2013) Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res;37(9):1041\u20131045","DOI":"10.1016\/j.leukres.2013.06.012"},{"issue":"4","key":"700_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3324\/haematol.2011.053348","volume":"97","author":"E Kuriakose","year":"2012","unstructured":"Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT (2012) Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 97(4):538\u2013542","journal-title":"Haematologica"},{"issue":"10","key":"700_CR35","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","volume":"38","author":"BT Huang","year":"2014","unstructured":"Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL (2014) Interferon-alpha2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 38(10):1177\u20131183","journal-title":"Leuk Res"},{"issue":"6","key":"700_CR36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","volume":"122","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Abdel-Wahab O, Manshouri T et al (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a. Blood 122(6):893\u2013901","journal-title":"Blood"},{"issue":"4","key":"700_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ajh.23928","volume":"90","author":"NC Them","year":"2015","unstructured":"Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R (2015) Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol 90(4):288\u2013294","journal-title":"Am J Hematol"},{"issue":"15","key":"700_CR38","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R (2015) Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126(15):1762\u20131769","journal-title":"Blood"},{"issue":"24","key":"700_CR39","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ (2015) Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations. Blood 126(24):2585\u20132591","journal-title":"Blood"},{"issue":"10","key":"700_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.exphem.2015.05.013","volume":"43","author":"KY King","year":"2015","unstructured":"King KY, Matatall KA, Shen CC, Goodell MA, Swierczek SI, Prchal JT (2015) Comparative long-term effects of interferon \u03b1 and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol 43(10):912\u2013918","journal-title":"Exp Hematol"},{"key":"700_CR41","unstructured":"Utke Rank C, Weis Bjerrum O, Larsen TS, Kj\u00e6r L, de Stricker K, Riley CH, Hasselbalch HC (2015) Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma; 1\u20137"},{"key":"700_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-016-0057-y","volume":"5","author":"M Kovacsovics-Bankowski","year":"2016","unstructured":"Kovacsovics-Bankowski M, Kelley TW, Efimova O, Kim SJ, Wilson A, Swierczek S, Prchal J (2016) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol 5:28 eCollection 2015","journal-title":"Exp Hematol Oncol"},{"key":"700_CR43","doi-asserted-by":"publisher","unstructured":"Kj\u00e6r L, Cordua S, Holmstr\u00f6m MO, Thomassen M, Kruse TA, Pallisgaard N, Larsen TS, de Stricker K, Skov V, Hasselbalch HC. Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment. PLoS One 2016;11(10):e0165336. doi: https:\/\/doi.org\/10.1371\/journal.pone.0165336 . eCollection 2016","DOI":"10.1371\/journal.pone.0165336"},{"issue":"5","key":"700_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00277-016-2631-0","volume":"95","author":"C O'Neill","year":"2016","unstructured":"O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C (2016) Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol 95(5):733\u2013738","journal-title":"Ann Hematol"},{"key":"700_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","volume":"54","author":"K Gowin","year":"2017","unstructured":"Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R (2017) Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res 54:73\u201377","journal-title":"Leuk Res"},{"issue":"4","key":"700_CR46","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S (2017) Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase2 trial. Lancet Haematol 4(4):e165\u2013e175. https:\/\/doi.org\/10.1016\/S2352-3026(17)30030-3 Epub 2017 Mar 11","journal-title":"Lancet Haematol"},{"key":"700_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","volume":"6","author":"L Masarova","year":"2017","unstructured":"Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S (2017) Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol 6:30. https:\/\/doi.org\/10.1186\/s40164-017-0090-5 eCollection 2017","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"700_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-017-0395-1","volume":"10","author":"E Cris\u00e0","year":"2017","unstructured":"Cris\u00e0 E, Cerrano M, Beggiato E, Benevolo G, Lanzarone G, Manzini PM, Borchiellini A, Riera L, Boccadoro M, Ferrero D (2017) Can pegylated interferon improve the outcome of polycythemia vera patients? J Hematol Oncol 10(1):15. https:\/\/doi.org\/10.1186\/s13045-017-0395-1","journal-title":"J Hematol Oncol"},{"key":"700_CR49","doi-asserted-by":"publisher","unstructured":"Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N, King KY, Hickman K, Litton S, Prchal JT (2018, 2018) Pegylated interferon alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. https:\/\/doi.org\/10.1038\/s41375-018-0080-6 [Epub ahead of print]","DOI":"10.1038\/s41375-018-0080-6"},{"issue":"5","key":"700_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/ejh.13034","volume":"100","author":"M Lindgren","year":"2018","unstructured":"Lindgren M, Samuelsson J, Nilsson L, Knutsen H, Ghanima W, Westin J, Johansson PL, Andr\u00e9asson B (2018) Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Eur J Haematol 100(5):419\u2013425","journal-title":"Eur J Haematol"},{"issue":"5","key":"700_CR51","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","volume":"10","author":"ME Bj\u00f8rn","year":"2017","unstructured":"Bj\u00f8rn ME, Hasselbalch HC (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Rev Hematol 10(5):393\u2013404","journal-title":"Expert Rev Hematol"},{"key":"700_CR52","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m MO, Hasselbalch HC (2018) Cancer immune therapy for myeloid malignancies \u2013 present and future. Sem Immunopathol Submitted","DOI":"10.1007\/s00281-018-0693-x"},{"issue":"5","key":"700_CR53","first-page":"123","volume":"12","author":"W Linkesch","year":"1985","unstructured":"Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H (1985) Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytosis. Acta Med Austriaca 12(5):123\u2013127","journal-title":"Acta Med Austriaca"},{"key":"700_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/BF00199157","volume":"25","author":"H Ludwig","year":"1987","unstructured":"Ludwig H, Linkesch W, Gisslinger H et al (1987) Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25:266\u2013273","journal-title":"Cancer Immunol Immunother"},{"issue":"Suppl 1","key":"700_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/10428199609074371","volume":"22","author":"E Lengfelder","year":"1996","unstructured":"Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22(Suppl 1):135\u2013142","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"700_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s002770050563","volume":"79","author":"E Lengfelder","year":"2000","unstructured":"Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79(3):103\u2013109","journal-title":"Ann Hematol"},{"key":"700_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(88)92881-4","volume":"2","author":"RT Silver","year":"1988","unstructured":"Silver RT (1988) Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2:403","journal-title":"Lancet"},{"key":"700_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","volume":"83","author":"HS Gilbert","year":"1998","unstructured":"Gilbert HS (1998) Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 83:1205\u20131213","journal-title":"Cancer"},{"key":"700_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.22026","volume":"107","author":"RT Silver","year":"2006","unstructured":"Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451\u2013458","journal-title":"Cancer"},{"issue":"8","key":"700_CR60","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","volume":"118","author":"CH Riley","year":"2011","unstructured":"Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM (2011) Increase in circulating CD4(+) CD25(+) Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neo- plasms during treatment with IFN-alpha. Blood 118(8):2170\u20132173","journal-title":"Blood"},{"issue":"3","key":"700_CR61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.12420","volume":"94","author":"CH Riley","year":"2015","unstructured":"Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Svane IM, Jensen MK (2015) Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1. Eur J Haematol 94(3):227\u2013234","journal-title":"Eur J Haematol"},{"issue":"1","key":"700_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12687","volume":"97","author":"CH Riley","year":"2016","unstructured":"Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, Svane IM (2016) Interferon-alpha induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2 -positive essential thrombocythemia and polycythemia vera. Eur J Haematol 97(1):83\u201392","journal-title":"Eur J Haematol"},{"issue":"9464","key":"700_CR63","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer genome project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061","journal-title":"Lancet"},{"key":"700_CR64","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, Staerk J, Delhommeau F, Lacout C, Gar\u00e7on L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature;434(7037):1144\u20131148","DOI":"10.1038\/nature03546"},{"issue":"17","key":"700_CR65","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloprolif- erative disorders. N Engl J Med 352(17):1779\u20131790","journal-title":"N Engl J Med"},{"issue":"4","key":"700_CR66","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397","journal-title":"Cancer Cell"},{"issue":"25","key":"700_CR67","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"25","key":"700_CR68","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405","journal-title":"N Engl J Med"},{"issue":"24","key":"700_CR69","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","volume":"123","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123(24):3714\u20133719","journal-title":"Blood"},{"key":"700_CR70","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cytogfr.2006.07.001","volume":"17","author":"A Billiau","year":"2006","unstructured":"Billiau A (2006) Interferon: the pathways of discovery 1. Molecular and cellular aspects. Cytokine Growth Factor Rev 17:381\u2013409","journal-title":"Cytokine Growth Factor Rev"},{"key":"700_CR71","first-page":"1048","volume":"8","author":"PP Dukes","year":"1980","unstructured":"Dukes PP, Izadi P, Ortega JA, Shora NA, Gomperts E (1980) Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture. Exp Hematol 8:1048","journal-title":"Exp Hematol"},{"key":"700_CR72","first-page":"2480","volume":"42","author":"E Lotzova","year":"1982","unstructured":"Lotzova E, Savary CA, Gutterman JU, Hersch EM (1982) Modulation of natural killer cell- mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 42:2480\u20132488","journal-title":"Cancer Res"},{"key":"700_CR73","first-page":"587","volume":"10","author":"HA Neumann","year":"1982","unstructured":"Neumann HA, Fauser AA (1982) Effect of interferon on pluripotent hematopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 10:587\u2013590","journal-title":"Exp Hematol"},{"key":"700_CR74","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.131.3.1300","volume":"131","author":"HE Broxmeyer","year":"1983","unstructured":"Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotent (CFU-GEMM), erytrhoid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131:1300\u20131305","journal-title":"J Immunol"},{"key":"700_CR75","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V70.4.1173.1173","volume":"70","author":"A Ganser","year":"1987","unstructured":"Ganser A, Carlo-Stella C, Greher J, Volkers B, Holzer D (1987) Effect of interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 70:1173\u20131179","journal-title":"Blood"},{"key":"700_CR76","first-page":"632","volume":"69","author":"MH Nissen","year":"1987","unstructured":"Nissen MH, Larsen JK, Plesner T, Olesen BK, Ernst P (1987) Alpha interferon induces enhanced expression of HLA-ABC antigens and beta2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells. Clin Exp Immunol 69:632\u2013638","journal-title":"Clin Exp Immunol"},{"key":"700_CR77","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","volume":"70","author":"C Carlo Stella","year":"1987","unstructured":"Carlo Stella C, Cazolla M, Ganser A et al (1987) Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70:1014\u20131019","journal-title":"Blood"},{"issue":"73","key":"700_CR78","first-page":"225","volume":"1988","author":"C Carlo Stella","year":"1988","unstructured":"Carlo Stella C, Cazzola M (1988) Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Hematologica 1988(73):225","journal-title":"Hematologica"},{"key":"700_CR79","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2141.1989.tb04251.x","volume":"71","author":"L Gugliotta","year":"1989","unstructured":"Gugliotta L, Bagnara GP, Catani L, Gaggiol L, Guarni A, Zauli G (1989) In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Br J Hematol 71:177\u2013181","journal-title":"Br J Hematol"},{"key":"700_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2141.1990.tb02531.x","volume":"74","author":"A Chott","year":"1990","unstructured":"Chott A, Gisslinger H, Thiele J et al (1990) Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Hematol 74:10\u201316","journal-title":"Br J Hematol"},{"key":"700_CR81","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF01698375","volume":"63","author":"CA Muller","year":"1991","unstructured":"Muller CA, Walz J, Zinser R, Buhring HJ, Steinke B, Schmidt H (1991) In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-alfa treatment. Ann Hematol 63:259\u2013263","journal-title":"Ann Hematol"},{"key":"700_CR82","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.V77.10.2103.2103","volume":"77","author":"H Wadenvik","year":"1991","unstructured":"Wadenvik H, Kutti J, Ridelli B et al (1991) The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77:2103\u20132108","journal-title":"Blood"},{"key":"700_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0344-0338(11)80116-0","volume":"189","author":"V Franco","year":"1993","unstructured":"Franco V, Florena AM, Aragona F, Campesi G (1993) Morphometric study of the bone marrow in polycythemia vera following interferon therapy. Pathol Res Pract 189:52\u201357","journal-title":"Pathol Res Pract"},{"key":"700_CR84","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1365-2141.1994.tb08324.x","volume":"87","author":"G Castello","year":"1994","unstructured":"Castello G, Lerza R, Cerruti A et al (1994) The in vitro effect of recombinant interferon-alpha-2a on circulating hematopoietic progenitors in polycythemia vera. Br J Hematol 87:621\u2013623","journal-title":"Br J Hematol"},{"issue":"Suppl 1","key":"700_CR85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10428199609074370","volume":"22","author":"C Peschel","year":"1996","unstructured":"Peschel C, Aulitzky WE, Huber C (1996) Influence of interferon \u2013alpha on cytokine expression by bone marrow microenvironment \u2013 impact on treatment of myeloproliferative disorders. Leukemia Lymphoma 22(Suppl 1):129\u2013134","journal-title":"Leukemia Lymphoma"},{"key":"700_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-0609.1997.tb00965.x","volume":"59","author":"D Grander","year":"1997","unstructured":"Grander D, Sangfelt O, Erickson S (1997) How does interferon exert its cell growth inhibitory effect? Eur J Hematol 59:129\u2013135","journal-title":"Eur J Hematol"},{"key":"700_CR87","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","volume":"96","author":"O Wang","year":"2000","unstructured":"Wang O, Miyakawa Y, Fox N et al (2000) Interferon-alfa directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96:2093\u20132097","journal-title":"Blood"},{"key":"700_CR88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","volume":"71","author":"DL Brassard","year":"2002","unstructured":"Brassard DL, Grace MJ, Bordens RW (2002) Interferon-alpha as an immunotherapeutic protein. J Leucocyte Biol 71:565\u2013581","journal-title":"J Leucocyte Biol"},{"key":"700_CR89","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","volume":"89","author":"M Ferrantini","year":"2007","unstructured":"Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89:884\u2013893","journal-title":"Biochimie"},{"key":"700_CR90","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1196\/annals.1415.030","volume":"1112","author":"L Bracci","year":"2007","unstructured":"Bracci L, Proietti E, Belardelli F (2007) IFN-alpha and novel strategies of combination therapy for cancer. Ann N Y Acad Sci 1112:256\u2013268","journal-title":"Ann N Y Acad Sci"},{"issue":"13","key":"700_CR91","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood.V96.13.4313","volume":"96","author":"D Xu","year":"2000","unstructured":"Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, Einhorn S, Pisa P, Grand\u00e9r D (2000) Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 96(13):4313\u20134318","journal-title":"Blood"},{"issue":"10","key":"700_CR92","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1056\/NEJMoa1503479","volume":"373","author":"GM Baerlocher","year":"2015","unstructured":"Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA et al (2015) Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 373(10):920\u2013928","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR93","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al (2015) A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 373(10):908\u2013919","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR94","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMe1508740","volume":"373","author":"M Armanios","year":"2015","unstructured":"Armanios M, Greider CW (2015) Treating myeloproliferation \u2014 on target or off? N. Engl. J Med 373(10):965\u2013966","journal-title":"N. Engl. J Med"},{"issue":"26","key":"700_CR95","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1056\/NEJMc1512663","volume":"373","author":"ME Bj\u00f8rn","year":"2015","unstructured":"Bj\u00f8rn ME, Nielsen CH, Hasselbalch HC (2015) Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N Engl J Med 373(26):2579\u20132580","journal-title":"N Engl J Med"},{"issue":"1","key":"700_CR96","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS (2015) Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol 43(1):78\u201389","journal-title":"Toxicol Pathol"},{"key":"700_CR97","doi-asserted-by":"crossref","unstructured":"Swierczek S, Kelley TW, King KY, Ching-Chieh S, Hickman K, Kim SJ, et al (2012) Salutary effect of pegylated interferon in PV and ET as evaluated by quantitation of Pre-JAK2V617F and JAK2V617F-bearing stem cells and granulocytes and correlation with circulating regulatory T cells and HSC cell cycle status. Blood 2012 (ASH Annu Meet Abstr 2012 120 Abstr 807)","DOI":"10.1182\/blood.V120.21.807.807"},{"issue":"12","key":"700_CR98","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","volume":"30","author":"MO Holmstr\u00f6m","year":"2016","unstructured":"Holmstr\u00f6m MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH (2016) The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 30(12):2413\u20132416","journal-title":"Leukemia"},{"issue":"2","key":"700_CR99","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/leu.2016.290","volume":"31","author":"MO Holmstr\u00f6m","year":"2017","unstructured":"Holmstr\u00f6m MO, Hjorts\u00f8 MD, Ahmad SM, Met \u00d6, Martinenaite E, Riley C et al (2017) The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 31(2):495\u2013498","journal-title":"Leukemia"},{"issue":"11","key":"700_CR100","doi-asserted-by":"publisher","first-page":"e1358334","DOI":"10.1080\/2162402X.2017.1358334","volume":"6","author":"MO Holmstr\u00f6m","year":"2017","unstructured":"Holmstr\u00f6m MO, Hasselbalch HC, Andersen MH (2017) The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy. Oncoimmunology 6(11):e1358334. https:\/\/doi.org\/10.1080\/2162402X.2017.1358334 eCollection 2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"700_CR101","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","volume":"32","author":"MO Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m MO, Martinenaite E, Ahmad SM, Met \u00d6, Friese C, Kj\u00e6r L (2018) The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32(2):429\u2013437","journal-title":"Leukemia"},{"issue":"6","key":"700_CR102","doi-asserted-by":"publisher","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","volume":"7","author":"MO Holmstr\u00f6m","year":"2018","unstructured":"Holmstr\u00f6m MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH (2018) Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. Oncoimmunology 7(6):e1433521. https:\/\/doi.org\/10.1080\/2162402X.2018.1433521 eCollection 2018","journal-title":"Oncoimmunology"},{"issue":"10","key":"700_CR103","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","volume":"54","author":"V Skov","year":"2013","unstructured":"Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW et al (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 54(10):2269\u20132273","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"700_CR104","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","volume":"9","author":"G Barosi","year":"2014","unstructured":"Barosi G (2014) An immune dysregulation in MPN. Curr Hematol Malig Rep 9(4):331\u2013339","journal-title":"Curr Hematol Malig Rep"},{"key":"700_CR105","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF et al (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118:6515\u20136520","journal-title":"Blood"},{"key":"700_CR106","first-page":"e289","volume":"2","author":"H Frederiksen","year":"2015","unstructured":"Frederiksen H, Farkas DK, Christiansen CF et al (2015) Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet. Haematol 2:e289\u2013e296","journal-title":"Haematol"},{"issue":"2","key":"700_CR107","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.12410","volume":"94","author":"H Pettersson","year":"2015","unstructured":"Pettersson H, Knutsen H, Holmberg E, Andr\u00e9asson B (2015) Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol 94(2):152\u2013156","journal-title":"Eur J Haematol"},{"key":"700_CR108","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ejh.12437","volume":"94","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC (2015) Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol 94:96\u201398","journal-title":"Eur J Haematol"},{"issue":"8","key":"700_CR109","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","volume":"58","author":"V Skov","year":"2017","unstructured":"Skov V, Riley CH, Thomassen M, Kj\u00e6r L, Stauffer Larsen T, Bjerrum OW, Kruse TA, Hasselbalch HC (2017) The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leuk Lymphoma 58(8):1914\u20131921","journal-title":"Leuk Lymphoma"},{"issue":"429","key":"700_CR110","doi-asserted-by":"publisher","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP et al (2018) Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10(429):eaam7729. https:\/\/doi.org\/10.1126\/scitranslmed.aam7729","journal-title":"Sci Transl Med"},{"issue":"11","key":"700_CR111","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/leu.2013.102","volume":"27","author":"C Marty","year":"2013","unstructured":"Marty C, Lacout C, Droin N, Le Cou\u00e9dic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I (2013) A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 27(11):2187\u20132195","journal-title":"Leukemia"},{"issue":"11","key":"700_CR112","doi-asserted-by":"publisher","first-page":"e112786","DOI":"10.1371\/journal.pone.0112786","volume":"9","author":"HC Hasselbalch","year":"2014","unstructured":"Hasselbalch HC, Thomassen M, Riley CH, Kj\u00e6r L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V (2014) Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One 9(11):e112786. https:\/\/doi.org\/10.1371\/journal.pone.0112786 eCollection 2014","journal-title":"PLoS One"},{"issue":"8","key":"700_CR113","doi-asserted-by":"publisher","first-page":"e0183620","DOI":"10.1371\/journal.pone.0183620","volume":"12","author":"M Andersen","year":"2017","unstructured":"Andersen M, Sajid Z, Pedersen RK, Gudmand-Hoeyer J, Ellervik C, Skov V (2017) Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS One 12(8):e0183620. https:\/\/doi.org\/10.1371\/journal.pone.0183620 eCollection 2017","journal-title":"PLoS One"},{"issue":"2","key":"700_CR114","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1084\/jem.20131043","volume":"211","author":"EM Pietras","year":"2014","unstructured":"Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, Passegu\u00e9 E (2014) Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 211(2):245\u2013262","journal-title":"J Exp Med"},{"issue":"18","key":"700_CR115","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T et al (2013) Depletion of Jak2V617F myeloproliferative neoplasm- propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood 121(18):3692\u201336702","journal-title":"Blood"},{"issue":"8","key":"700_CR116","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","volume":"122","author":"S Hasan","year":"2013","unstructured":"Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W et al (2013) JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood 122(8):1464\u20131477. https:\/\/doi.org\/10.1182\/blood-2013-04-498956","journal-title":"Blood"},{"issue":"14","key":"700_CR117","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1002\/cncr.30676","volume":"123","author":"HC Hasselbalch","year":"2017","unstructured":"Hasselbalch HC (2017) Molecular profiling as a novel tool to predict response to interferon-\u03b12 in MPNs: the proof of concept in early myelofibrosis. Cancer 123(14):2600\u20132603","journal-title":"Cancer"},{"issue":"4","key":"700_CR118","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jir.2012.0120","volume":"33","author":"BL Stein","year":"2013","unstructured":"Stein BL, Tiu RV (2013) Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interf Cytokine Res 33(4):145\u2013153","journal-title":"J Interf Cytokine Res"},{"issue":"23","key":"700_CR119","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355(23):2452\u20132466","journal-title":"N Engl J Med"},{"key":"700_CR120","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1155\/2015\/102476","volume":"102476","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm 102476:2015. https:\/\/doi.org\/10.1155\/2015\/102476","journal-title":"Mediat Inflamm"},{"issue":"10","key":"700_CR121","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232","journal-title":"J Clin Oncol"},{"key":"700_CR122","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2015.11.017","volume":"41","author":"AL S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen AL, Hasselbalch HC (2016) Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 41:27\u201335","journal-title":"Leuk Res"},{"key":"700_CR123","doi-asserted-by":"publisher","unstructured":"Enblom-Larsson A, Girodon F, Bak M, Hersby D, Jooste V, Hasselbalch HC, Johansson P, Andreasson B (2017) A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.14625 [Epub ahead of print]","DOI":"10.1111\/bjh.14625"},{"issue":"2","key":"700_CR124","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC (2013) Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 37(2):214\u2013220","journal-title":"Leuk Res"},{"key":"700_CR125","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119:3219\u20133225","journal-title":"Blood"},{"issue":"2","key":"700_CR126","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24(2):133\u2013145","journal-title":"Cytokine Growth Factor Rev"},{"key":"700_CR127","doi-asserted-by":"publisher","first-page":"145293","DOI":"10.1155\/2015\/14529","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediat Inflamm 2015:145293. https:\/\/doi.org\/10.1155\/2015\/14529","journal-title":"Mediat Inflamm"},{"issue":"5","key":"700_CR128","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC et al (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30(5):1018\u20131024","journal-title":"Leukemia"},{"key":"700_CR129","doi-asserted-by":"crossref","unstructured":"Geyer HL, Dueck AC, Scherber RM, Mesa R (2015) Impact of inflammation on myeloproliferative neoplasm symptom burden. Mediat Inflamm 2015:284706","DOI":"10.1155\/2015\/284706"},{"issue":"8","key":"700_CR130","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaophthalmol.2017.2011","volume":"135","author":"M Bak","year":"2017","unstructured":"Bak M, S\u00f8rensen TL, Flachs EM, Zwisler AD, Juel K, Frederiksen H, Hasselbalch HC (2017) Age-related macular degeneration in patients with chronic myeloproliferative neoplasms. JAMA Ophthalmol 135(8):835\u2013843","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"700_CR131","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","volume":"38","author":"AS Christensen","year":"2014","unstructured":"Christensen AS, M\u00f8ller JB, Hasselbalch HC (2014) Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 38(4):490\u2013495","journal-title":"Leuk Res"},{"issue":"5","key":"700_CR132","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/bjh.12581","volume":"163","author":"S Farmer","year":"2013","unstructured":"Farmer S, Horv\u00e1th-Puh\u00f3 E, Vestergaard H, Hermann AP, Frederiksen H (2013) Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol 163(5):603\u2013610","journal-title":"Br J Haematol"},{"issue":"4","key":"700_CR133","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/17474086.2015.1053456","volume":"8","author":"S Farmer","year":"2015","unstructured":"Farmer S, Ocias LF, Vestergaard H, Broesby-Olsen S, Hermann AP, Frederiksen H (2015) Bone morbidity in chronic myeloproliferative neoplasms. Expert Rev Hematol 8(4):447\u2013456","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"700_CR134","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00198-016-3788-z","volume":"28","author":"S Farmer","year":"2017","unstructured":"Farmer S, Shanbhogue VV, Hansen S, Stahlberg CI, Vestergaard H, Hermann AP, Frederiksen H (2017) Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. Osteoporos Int 28(2):677\u2013668","journal-title":"Osteoporos Int"},{"key":"700_CR135","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","volume":"85","author":"F Lussana","year":"2017","unstructured":"Lussana F, Rambaldi A (2017) Inflammation and myeloproliferative neoplasms. Autoimmun 85:58\u201363. https:\/\/doi.org\/10.1016\/j.jaut.2017.06.010 Epub 2017 Jun 30","journal-title":"Autoimmun"},{"issue":"10(1)","key":"700_CR136","first-page":"1054","volume":"22","author":"F Lussana","year":"2017","unstructured":"Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B et al (2017) Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 22(10(1)):1054","journal-title":"J Hematol Oncol"},{"key":"700_CR137","doi-asserted-by":"publisher","unstructured":"Craver BM, El Alaoui K, Scherber RM, Fleischman AG (2018) The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers 10(4). https:\/\/doi.org\/10.3390\/cancers10040104","DOI":"10.3390\/cancers10040104"},{"issue":"1","key":"700_CR138","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"7007","key":"700_CR139","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature02924","volume":"431","author":"E Pikarsky","year":"2004","unstructured":"Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation associated cancer. Nature 431(7007):461\u2013466","journal-title":"Nature"},{"issue":"9","key":"700_CR140","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/eji.201141727","volume":"41","author":"MJ Pittet","year":"2011","unstructured":"Pittet MJ, Swirski FK (2011) Monocytes link atherosclerosis and cancer. Eur J Immunol 41(9):2519\u20132522","journal-title":"Eur J Immunol"},{"key":"700_CR141","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.leukres.2018.02.008","volume":"67","author":"TI Mughal","year":"2018","unstructured":"Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE et al (2018) Recent advances in the genomics and therapy of BCR\/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res 67:67\u201374","journal-title":"Leuk Res"},{"issue":"1","key":"700_CR142","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","volume":"87","author":"V Skov","year":"2011","unstructured":"Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC (2011) Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 87(1):54\u201360","journal-title":"Eur J Haematol"},{"key":"700_CR143","doi-asserted-by":"crossref","unstructured":"Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC (2012) Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res;36(11):1387\u20131392","DOI":"10.1016\/j.leukres.2012.07.009"},{"issue":"9","key":"700_CR144","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","volume":"40","author":"V Skov","year":"2012","unstructured":"Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS (2012) Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 40(9):771\u2013780","journal-title":"Exp Hematol"},{"key":"700_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-015-0194-3","volume":"22","author":"AV Belikov","year":"2015","unstructured":"Belikov AV, Schraven B, Simeoni L (2015) T cells and reactive oxygen species. J Biomed Sci 22:1\u201311","journal-title":"J Biomed Sci"},{"key":"700_CR146","doi-asserted-by":"crossref","unstructured":"Chen X, Song M, Zhang B, Zhang Y (2016) Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxid Med Cell Longev; 11\u201316","DOI":"10.1155\/2016\/1580967"},{"key":"700_CR147","doi-asserted-by":"publisher","first-page":"648090","DOI":"10.1155\/2015\/648090","volume":"2015","author":"ME Bj\u00f8rn","year":"2015","unstructured":"Bj\u00f8rn ME, Hasselbalch HC (2015) The role of reactive oxygen species in myelofibrosis and related neoplasms. Mediat Inflamm 2015:648090. https:\/\/doi.org\/10.1155\/2015\/648090","journal-title":"Mediat Inflamm"},{"key":"700_CR148","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377:111\u2013121","journal-title":"N Engl J Med"},{"issue":"2","key":"700_CR149","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","volume":"125","author":"T Kameda","year":"2015","unstructured":"Kameda T, Shide K, Yamaja T et al (2015) Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125(2):304\u2013315","journal-title":"Blood"},{"key":"700_CR150","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A et al (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11\u201324","journal-title":"Cancer Cell"},{"issue":"13","key":"700_CR151","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2011-12-380113","volume":"119","author":"H Takizawa","year":"2012","unstructured":"Takizawa H, Boettcher S, Manz MG (2012) Demand \u2013adapted regulation of early hematopoiesis in infection and inflammation. Blood 119(13):2991\u20133002","journal-title":"Blood"},{"issue":"14","key":"700_CR152","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220\u20132228","journal-title":"Blood"},{"key":"700_CR153","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DA, Nangalia J et al (2015) Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 372:601\u2013612","journal-title":"N Engl J Med"},{"issue":"7","key":"700_CR154","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ajh.24740","volume":"92","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Gangat N et al (2017) Monocytosis in polycythemia vera: clinical and molecular correlates. Am J Hematol 92(7):640\u2013645","journal-title":"Am J Hematol"},{"issue":"8642","key":"700_CR155","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S0140-6736(89)92273-3","volume":"1","author":"MT Boyd","year":"1989","unstructured":"Boyd MT, Maclean N, Oscier DG (1989) Detection of retrovirus in patients with myeloproliferative disease. Lancet 1(8642):814\u2013817","journal-title":"Lancet"},{"issue":"6","key":"700_CR156","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.exphem.2004.03.003","volume":"32","author":"D Morgan","year":"2004","unstructured":"Morgan D, Brodsky I (2004) Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells. Exp Hematol 32(6):520\u2013525","journal-title":"Exp Hematol"},{"issue":"26","key":"700_CR157","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","volume":"315","author":"HF Dvorak","year":"1986","unstructured":"Dvorak HF (1986) Tumors: wounds that do not heal, Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650\u20131659","journal-title":"N Engl J Med"},{"key":"700_CR158","first-page":"2489","volume":"34","author":"J Kissova","year":"2014","unstructured":"Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I (2014) Second malignancies in Philadelphia-negative myeloproliferative neoplasms- single-center experience. Anticancer Res 34:2489\u20132496","journal-title":"Anticancer Res"},{"issue":"1","key":"700_CR159","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ejh.12787","volume":"98","author":"IO Hansen","year":"2017","unstructured":"Hansen IO, S\u00f8rensen AL, Hasselbalch HC (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol 98(1):75\u201384","journal-title":"Eur J Haematol"},{"issue":"7","key":"700_CR160","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118(7):1723\u20131735","journal-title":"Blood"},{"issue":"1","key":"700_CR161","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2012","unstructured":"Challen GA, Sun D, Jeong M et al (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44(1):23\u201331","journal-title":"Nat Genet"},{"issue":"1","key":"700_CR162","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronn\u2019e L, Della Valle V et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1):25\u201338","journal-title":"Cancer Cell"},{"issue":"17","key":"700_CR163","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","volume":"118","author":"Z Li","year":"2011","unstructured":"Li Z, Cai X, Cai CL et al (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118(17):4509\u20134518","journal-title":"Blood"},{"issue":"6","key":"700_CR164","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553\u2013567","journal-title":"Cancer Cell"},{"issue":"8","key":"700_CR165","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/leu.2010.120","volume":"24","author":"JJ Kiladjian","year":"2010","unstructured":"Kiladjian JJ, Masse A, Cassinat B et al (2010) French intergroup of myeloproliferative neoplasms (FIM). Clinical analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24(8):1519\u20131523","journal-title":"Leukemia"},{"issue":"35","key":"700_CR166","doi-asserted-by":"publisher","first-page":"14566","DOI":"10.1073\/pnas.1112317108","volume":"108","author":"M Ko","year":"2011","unstructured":"Ko M, Bandukwala HS, An J et al (2011) Ten-eleventranslocation2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108(35):14566\u201314571","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7413","key":"700_CR167","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature11323","volume":"488","author":"M Sasaki","year":"2012","unstructured":"Sasaki M, Knobbe CB, Munger JC et al (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488(7413):656\u2013659","journal-title":"Nature"},{"key":"700_CR168","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30679","volume":"123","author":"RT Silver","year":"2017","unstructured":"Silver RT, Barela A, Lascu E et al (2017) The effect of initial molecular profile on response to recombinant interferon alfa (rIFNa) treatment in early myelofibrosis. Cancer 123:2680\u20132687","journal-title":"Cancer"},{"key":"700_CR169","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/leu.2009.90","volume":"23","author":"RT Silver","year":"2009","unstructured":"Silver RT, Vandris K (2009) Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early myelofibrosis. Leukemia 23:1366\u20131369","journal-title":"Leukemia"},{"key":"700_CR170","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ (2011) Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117:6669\u20136672","journal-title":"Blood"},{"key":"700_CR171","doi-asserted-by":"crossref","unstructured":"Pizzi M, Silver RT, Barel A, Orazi A Recombinant interferon-a in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28:1315\u20131323","DOI":"10.1038\/modpathol.2015.93"},{"key":"700_CR172","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1600-0609.2008.01183.x","volume":"82","author":"V Buxhofer-Ausch","year":"2009","unstructured":"Buxhofer-Ausch V, Gisslinger H, Berg T et al (2009) Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol 82:161\u2013163","journal-title":"Eur J Haematol"},{"issue":"2","key":"700_CR173","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/onc.2011.221","volume":"31","author":"HF Wei-Chun","year":"2012","unstructured":"Wei-Chun HF, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY (2012) Inflammatory signaling compromises cell responses to interferon. Oncogene 31(2):161\u2013172","journal-title":"Oncogene"},{"key":"700_CR174","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/107327480801500302","volume":"15","author":"JL Messina","year":"2008","unstructured":"Messina JL, Yu H, Riker AI, Munster PN, Jove RI, Daud AI (2008) Activated STAT-3 in melanoma. Cancer Control 15:196\u2013201","journal-title":"Cancer Control"},{"key":"700_CR175","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jhep.2006.01.037","volume":"45","author":"DD Bona","year":"2006","unstructured":"Bona DD, Cippitelli M, Fionda C, Camma C, Licata A, Santoni A, Craxi A (2006) Oxidative stress inhibits IFN-alpha2-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 45:271\u2013279","journal-title":"J Hepatol"},{"key":"700_CR176","doi-asserted-by":"publisher","unstructured":"Hasselbalch HC (2015) Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res pii: S0145-2126(15)30373\u20138. doi: https:\/\/doi.org\/10.1016\/j.leukres.2015.09.002 . [Epub ahead of print]","DOI":"10.1016\/j.leukres.2015.09.002"},{"issue":"2","key":"700_CR177","first-page":"73","volume":"3","author":"ME Bj\u00f8rn","year":"2014","unstructured":"Bj\u00f8rn ME, de Stricker K, Kj\u00e6r L, Ellemann K, Hasselbalch HC (2014) Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep 3(2):73\u201375","journal-title":"Leuk Res Rep"},{"key":"700_CR178","doi-asserted-by":"publisher","unstructured":"Mikkelsen SU, Kjaer L, Bj\u00f8rn ME, Knudsen TA, S\u00f8rensen AL, Andersen CBL et al (2018) Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med 2018 Jun 22. doi: https:\/\/doi.org\/10.1002\/cam4.1619 . [Epub ahead of print]","DOI":"10.1002\/cam4.1619"},{"issue":"10","key":"700_CR179","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","volume":"30","author":"HC Hasselbalch","year":"2006","unstructured":"Hasselbalch HC, Riley CH (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 30(10):1217\u20131225","journal-title":"Leuk Res"},{"key":"700_CR180","first-page":"20","volume":"6","author":"AL S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen AL, Kallenbach K, Hasselbalch HC (2016) A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leuk Res Rep 6:20\u201333","journal-title":"Leuk Res Rep"},{"issue":"19","key":"700_CR181","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792\u20131802","journal-title":"N Engl J Med"},{"key":"700_CR182","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399\u2013401","journal-title":"Nature"},{"issue":"10","key":"700_CR183","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.leukres.2014.07.006","volume":"38","author":"HC Hasselbalch","year":"2014","unstructured":"Hasselbalch HC (2014) The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 38(10):1230\u20131236","journal-title":"Leuk Res"},{"issue":"1","key":"700_CR184","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.12099","volume":"160","author":"C Nielsen","year":"2013","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70\u201379","journal-title":"Br J Haematol"},{"key":"700_CR185","doi-asserted-by":"publisher","unstructured":"Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Rou\u00e9 I et al (2018) Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma. 2018 :1-9. doi: https:\/\/doi.org\/10.1080\/10428194.2018.1441408 . [Epub ahead of print]","DOI":"10.1080\/10428194.2018.1441408"},{"key":"700_CR186","doi-asserted-by":"crossref","unstructured":"Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL (2011). Interferon-\u03b1 in acute myeloid leukemia: an old drug revisited. Leukemia;25(5):739\u2013748","DOI":"10.1038\/leu.2010.324"},{"issue":"19","key":"700_CR187","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","volume":"116","author":"S Thepot","year":"2010","unstructured":"Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Groupe Francophone des Myelodysplasies (GFM) et al (2010) treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116(19):3735\u20133742","journal-title":"Blood"},{"issue":"2","key":"700_CR188","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","volume":"93","author":"R Assi","year":"2018","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X et al (2018) A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol 93(2):277\u2013285","journal-title":"Am J Hematol"},{"issue":"5","key":"700_CR189","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974\u2013986","journal-title":"Cell"},{"issue":"5","key":"700_CR190","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961\u2013973","journal-title":"Cell"},{"key":"700_CR191","doi-asserted-by":"crossref","unstructured":"Aaboe-J\u00f8rgensen M, Holmstr\u00f8m MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH (2018) Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology doi: 10.1080\/2162402X.2018.1468957","DOI":"10.1080\/2162402X.2018.1468957"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-018-0700-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-018-0700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-018-0700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:23:46Z","timestamp":1693873426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-018-0700-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":191,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00281-018-0700-2","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No authors have conflicts of interest to disclose. However, it should be noted that Morten Orebo Holmstr\u00f6m and Hans Carl Hasselbalch together with Mads Hald Andersen have filed a patent regarding the <i>CALR<\/i> exon 9 mutations and <i>JAK2<\/i>V61F-mutation as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region, and Copenhagen University Hospital at Herlev, Capital Region, according to Danish Law concerning inventions made at public research institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}